In regard to the therapeutic effect of IL-4 on the course of MS, G. Casella et al. showed that IL-4 administration significantly modulated neuroinflammation and also significantly reduced clinical symptoms in experimental autoimmune encephalitis, spinal myelitis and a mouse model of MS. The gene discussed is IL4; the disease is myeloid sarcoma.